Paolo Pertile

Personal Details

First Name:	Paolo
Middle Name:
Last Name:	Pertile
Suffix:
RePEc Short-ID:	ppe336
	[This author has chosen not to make the email address public]

Affiliation

Dipartimento di Scienze Economiche
Facoltà di Economia
Università degli Studi di Verona

Verona, Italy
http://www.dse.univr.it/
RePEc:edi:isverit (more details at EDIRC)

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:

1. Rosella Levaggi & Paolo Pertile, 2020. "Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition”," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 455-456, June.

   Mentioned in:

   1. Chris Sampson’s journal round-up for 1st June 2020
      by Chris Sampson in The Academic Health Economists' Blog on 2020-06-01 11:00:00
2. Rosella Levaggi & Paolo Pertile, 2020. "Which valued‐based price when patients are heterogeneous?," Health Economics, John Wiley & Sons, Ltd., vol. 29(8), pages 923-935, August.

   Mentioned in:

   1. Grace Li’s journal round-up for 20th July 2020
      by Grace Li in The Academic Health Economists' Blog on 2020-07-20 11:00:08
3. Rosella Levaggi & Michele Moretto & Paolo Pertile, 2013. "The dynamics of pharmaceutical regulation and R&D investments," Working Papers 13/2013, University of Verona, Department of Economics.
   • Rosella Levaggi & Michele Moretto & Paolo Pertile, 2017. "The Dynamics of Pharmaceutical Regulation and R&D Investments," Journal of Public Economic Theory, Association for Public Economic Theory, vol. 19(1), pages 121-141, February.

   Mentioned in:

   1. #HEJC papers for September 2013
      by academichealtheconomists in The Academic Health Economists' Blog on 2013-09-01 04:01:38
4. Rosella Levaggi & Paolo Pertile, 2020. "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 357-362, June.

   Mentioned in:

   1. Chris Sampson’s journal round-up for 1st June 2020
      by Chris Sampson in The Academic Health Economists' Blog on 2020-06-01 11:00:00
5. Simona Gamba & Paolo Pertile & Sabine Vogler, 2020. "The impact of managed entry agreements on pharmaceutical prices," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 47-62, October.

   Mentioned in:

   1. Chris Sampson’s journal round-up for 28th December 2020
      by Chris Sampson in The Academic Health Economists' Blog on 2020-12-28 12:00:00

Working papers

1. Simona Gamba & Laura Magazzini & Paolo Pertile, 2019. "R&D and market size: who benefits from orphan drug regulation?," Working Papers 09/2019, University of Verona, Department of Economics.

   Cited by:

   1. Massimo FLORIO, 2020. "Biomed Europa: after the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly," CIRIEC Working Papers 2008, CIRIEC - Université de Liège.
      • Massimo Florio & Simona Gamba, 2021. "Biomed Europa: After the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly," Annals of Public and Cooperative Economics, Wiley Blackwell, vol. 92(3), pages 387-409, September.

2. Paolo Pertile & Simona Gamba & Martin Forster, 2018. "Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence," Discussion Papers 18/04, Department of Economics, University of York.

   Cited by:

   1. Kyle, Margaret K., 2022. "Incentives for pharmaceutical innovation: What’s working, what’s lacking," International Journal of Industrial Organization, Elsevier, vol. 84(C).
   2. Gamba, S.; & Pertile, P.; & Righetti, G.;, 2022. "Spillovers of Pharmaceutical Price Regulations: evidence from the AMNOG Reform in Germany," Health, Econometrics and Data Group (HEDG) Working Papers 22/20, HEDG, c/o Department of Economics, University of York.

3. Rosella Levaggi & Paolo Pertile, 2016. "Pricing policies when patients are heterogeneous: a welfare analysis," Working Papers 17/2016, University of Verona, Department of Economics.

   Cited by:

   1. Gregory J. Critchley & Gregory S. Zaric, 2019. "The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare," Health Economics, John Wiley & Sons, Ltd., vol. 28(8), pages 1035-1051, August.
   2. Rosella Levaggi & Paolo Pertile, 2020. "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 357-362, June.

4. Sebastian Jobjornsson & Martin Forster & Paolo Pertile & Carl-Fredrik Burman, 2015. "Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation," Discussion Papers 15/16, Department of Economics, University of York.
   • Jobjörnsson, Sebastian & Forster, Martin & Pertile, Paolo & Burman, Carl-Fredrik, 2016. "Late-stage pharmaceutical R&D and pricing policies under two-stage regulation," Journal of Health Economics, Elsevier, vol. 50(C), pages 298-311.

   Cited by:

   1. Brekke, Kurt R. & Dalen, Dag Morten & Straume, Odd Rune, 2023. "The price of cost-effectiveness thresholds," Discussion Paper Series in Economics 4/2023, Norwegian School of Economics, Department of Economics.
      • Kurt R. Brekke & Dag Morten Dalen & Odd Rune Straume, 2022. "The price of cost-effectiveness thresholds," NIPE Working Papers 5/2022, NIPE - Universidade do Minho.
   2. Massimo FLORIO, 2020. "Biomed Europa: after the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly," CIRIEC Working Papers 2008, CIRIEC - Université de Liège.
      • Massimo Florio & Simona Gamba, 2021. "Biomed Europa: After the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly," Annals of Public and Cooperative Economics, Wiley Blackwell, vol. 92(3), pages 387-409, September.
   3. Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).
   4. Löblová, Olga & Csanádi, Marcell & Ozierański, Piotr & Kaló, Zoltán & King, Lawrence & McKee, Martin, 2019. "Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology," Health Policy, Elsevier, vol. 123(7), pages 630-634.
   5. Joan Costa‐Font & Rosella Levaggi, 2020. "Innovation, aging, and health care: Unraveling “silver” from “red” herrings?," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 3-7, October.
   6. Brekke, Kurt R. & Dalen, Dag Morten & Straume, Odd Rune, 2023. "The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets," Journal of Health Economics, Elsevier, vol. 90(C).
   7. Andres Alban & Stephen E. Chick & Martin Forster, 2023. "Value-Based Clinical Trials: Selecting Recruitment Rates and Trial Lengths in Different Regulatory Contexts," Management Science, INFORMS, vol. 69(6), pages 3516-3535, June.
   8. Simona Gamba & Laura Magazzini & Paolo Pertile, 2019. "R&D and market size: who benefits from orphan drug regulation?," Working Papers 09/2019, University of Verona, Department of Economics.
   9. Reza Mahjoub & Fredrik Ødegaard & Gregory S. Zaric, 2018. "Evaluation of a pharmaceutical risk‐sharing agreement when patients are screened for the probability of success," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 15-25, January.
   10. Simona Gamba & Paolo Pertile & Sabine Vogler, 2020. "The impact of managed entry agreements on pharmaceutical prices," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 47-62, October.

5. Alessandro Bucciol & Laura Cavalli & Igor Fedotenkov & Paolo Pertile & Veronica Polin & Nicola Sartor & Alessandro Sommacal, 2015. "Public policies over the life cycle: a large scale OLG model for France, Italy and Sweden," Working Papers 29/2015, University of Verona, Department of Economics.

   Cited by:

   1. Bucciol, Alessandro & Cavalli, Laura & Fedotenkov, Igor & Pertile, Paolo & Polin, Veronica & Sartor, Nicola & Sommacal, Alessandro, 2017. "A large scale OLG model for the analysis of the redistributive effects of policy reforms," European Journal of Political Economy, Elsevier, vol. 48(C), pages 104-127.
   2. Michele Catalano & Emilia Pezzolla, 2016. "The effects of education and aging in an OLG model: long-run growth in France, Germany and Italy," Empirica, Springer;Austrian Institute for Economic Research;Austrian Economic Association, vol. 43(4), pages 757-800, November.

6. Stephen Chick & Martin Forster & Paolo Pertile, 2015. "A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response," Discussion Papers 15/09, Department of Economics, University of York.
   • Stephen Chick & Martin Forster & Paolo Pertile, 2017. "A Bayesian decision theoretic model of sequential experimentation with delayed response," Journal of the Royal Statistical Society Series B, Royal Statistical Society, vol. 79(5), pages 1439-1462, November.

   Cited by:

   1. Amir Ali Nasrollahzadeh & Amin Khademi, 2022. "Dynamic Programming for Response-Adaptive Dose-Finding Clinical Trials," INFORMS Journal on Computing, INFORMS, vol. 34(2), pages 1176-1190, March.
   2. Nikhil Bhat & Vivek F. Farias & Ciamac C. Moallemi & Deeksha Sinha, 2020. "Near-Optimal A-B Testing," Management Science, INFORMS, vol. 66(10), pages 4477-4495, October.
   3. Arielle Anderer & Hamsa Bastani & John Silberholz, 2022. "Adaptive Clinical Trial Designs with Surrogates: When Should We Bother?," Management Science, INFORMS, vol. 68(3), pages 1982-2002, March.
   4. Andres Alban & Stephen E. Chick & Martin Forster, 2023. "Value-Based Clinical Trials: Selecting Recruitment Rates and Trial Lengths in Different Regulatory Contexts," Management Science, INFORMS, vol. 69(6), pages 3516-3535, June.
   5. Andres Alban & Stephen E. Chick & Martin Forster, 2020. "Value-based clinical trials: selecting trial lengths and recruitment rates in different regulatory contexts," Discussion Papers 20/01, Department of Economics, University of York.
   6. Thijssen, Jacco J.J. & Bregantini, Daniele, 2017. "Costly sequential experimentation and project valuation with an application to health technology assessment," Journal of Economic Dynamics and Control, Elsevier, vol. 77(C), pages 202-229.
   7. Williamson, S. Faye & Jacko, Peter & Jaki, Thomas, 2022. "Generalisations of a Bayesian decision-theoretic randomisation procedure and the impact of delayed responses," Computational Statistics & Data Analysis, Elsevier, vol. 174(C).
   8. Panos Kouvelis & Joseph Milner & Zhili Tian, 2017. "Clinical Trials for New Drug Development: Optimal Investment and Application," Manufacturing & Service Operations Management, INFORMS, vol. 19(3), pages 437-452, July.
   9. Vishal Ahuja & John R. Birge, 2020. "An Approximation Approach for Response-Adaptive Clinical Trial Design," INFORMS Journal on Computing, INFORMS, vol. 32(4), pages 877-894, October.
   10. Stephen E. Chick & Noah Gans & Özge Yapar, 2022. "Bayesian Sequential Learning for Clinical Trials of Multiple Correlated Medical Interventions," Management Science, INFORMS, vol. 68(7), pages 4919-4938, July.

7. Alessandro Bucciol & Laura Cavalli & Elena Dalla Chiara & Martina Menon & Paolo Pertile & Veronica Polin & Alessandro Sommacal, 2014. "L’ISEE in Italia: Una Nota Metodologica Partendo dai Dati IT-SILC," Working Papers 06/2014, University of Verona, Department of Economics.

   Cited by:

   1. Alessandro Bucciol & Laura Cavalli & Paolo Pertile & Veronica Polin & Alessandro Sommacal, 2016. "Redistribution at the local level: the case of public childcare in Italy," International Review of Economics, Springer;Happiness Economics and Interpersonal Relations (HEIRS), vol. 63(4), pages 359-378, December.
      • Alessandro Bucciol & Laura Cavalli & Paolo Pertile & Veronica Polin & Alessandro Sommacal, 2013. "Redistribution at the Local Level: The Case of Public Childcare in Italy," Working Papers 21/2013, University of Verona, Department of Economics.
   2. Giovanni Gallo, 2021. "Regional Support for the National Government: Joint Effects of Minimum Income Schemes in Italy," Italian Economic Journal: A Continuation of Rivista Italiana degli Economisti and Giornale degli Economisti, Springer;Società Italiana degli Economisti (Italian Economic Association), vol. 7(1), pages 149-185, March.
   3. Daniela Del Boca & Chiara Pronzato & Giuseppe Sorrenti, 2016. "When Rationing Plays a Role: Selection Criteria in the Italian Early Childcare System," CESifo Economic Studies, CESifo Group, vol. 62(4), pages 752-775.
      • Daniela Del Boca & Chiara Pronzato & Giuseppe Sorrenti, 2015. "When rationing plays a role: selection criteria in the Italian early child care system," Carlo Alberto Notebooks 399, Collegio Carlo Alberto.
   4. Del Boca, Daniela & Pronzato, Chiara & Sorrenti, Giuseppe, 2016. "When rationing plays a Role," CEPR Discussion Papers 11574, C.E.P.R. Discussion Papers.

8. Alessandro Bucciol & Laura Cavalli & Paolo Pertile & Veronica Polin & Alessandro Sommacal, 2013. "Redistribution at the Local Level: The Case of Public Childcare in Italy," Working Papers 21/2013, University of Verona, Department of Economics.
   • Alessandro Bucciol & Laura Cavalli & Paolo Pertile & Veronica Polin & Alessandro Sommacal, 2016. "Redistribution at the local level: the case of public childcare in Italy," International Review of Economics, Springer;Happiness Economics and Interpersonal Relations (HEIRS), vol. 63(4), pages 359-378, December.

   Cited by:

   1. Suárez-Varela, Marta & Martínez-Espiñeira, Roberto & González-Gómez, Francisco, 2015. "An analysis of the price escalation of non-linear water tariffs for domestic uses in Spain," Utilities Policy, Elsevier, vol. 34(C), pages 82-93.
   2. Braga, Michela & Scervini, Francesco, 2017. "The performance of politicians: The effect of gender quotas," European Journal of Political Economy, Elsevier, vol. 46(C), pages 1-14.
      • Michela Braga & Francesco Scervini, 2015. "The performance of politicians. The effect of gender quotas," Working papers 35, Società Italiana di Economia Pubblica.
   3. Luigi Brighi & Paolo Silvestri, 2019. "Inefficiency in Childcare Production: Evidence from Italian Microdata," Italian Economic Journal: A Continuation of Rivista Italiana degli Economisti and Giornale degli Economisti, Springer;Società Italiana degli Economisti (Italian Economic Association), vol. 5(1), pages 103-133, March.
   4. Marta Suárez-Varela & Roberto Martínez-Espiñeira, 2018. "A proposal for the analysis of price escalation within water tariffs: The impact of the Water Framework Directive in Spain," Environment and Planning C, , vol. 36(4), pages 726-749, June.

9. Rosella Levaggi & Michele Moretto & Paolo Pertile, 2013. "The dynamics of pharmaceutical regulation and R&D investments," Working Papers 13/2013, University of Verona, Department of Economics.
   • Rosella Levaggi & Michele Moretto & Paolo Pertile, 2017. "The Dynamics of Pharmaceutical Regulation and R&D Investments," Journal of Public Economic Theory, Association for Public Economic Theory, vol. 19(1), pages 121-141, February.

   Cited by:

   1. Brekke, Kurt R. & Dalen, Dag Morten & Straume, Odd Rune, 2023. "The price of cost-effectiveness thresholds," Discussion Paper Series in Economics 4/2023, Norwegian School of Economics, Department of Economics.
      • Kurt R. Brekke & Dag Morten Dalen & Odd Rune Straume, 2022. "The price of cost-effectiveness thresholds," NIPE Working Papers 5/2022, NIPE - Universidade do Minho.
   2. Raisa Pérez-Vas & Félix Puime Guillén & Joaquín Enríquez-Díaz, 2021. "Valuation of a Company Producing and Trading Seaweed for Human Consumption: Classical Methods vs. Real Options," IJERPH, MDPI, vol. 18(10), pages 1-13, May.
   3. Paolo Pertile & Simona Gamba & Martin Forster, 2018. "Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence," Discussion Papers 18/04, Department of Economics, University of York.
   4. Brekke, Kurt R. & Dalen, Dag Morten & Straume, Odd Rune, 2023. "The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets," Journal of Health Economics, Elsevier, vol. 90(C).
   5. Fernando Antonanzas & Carmelo Juárez-Castelló & Reyes Lorente & Roberto Rodríguez-Ibeas, 2019. "The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments," PharmacoEconomics, Springer, vol. 37(12), pages 1469-1483, December.
   6. Simona Gamba & Paolo Pertile & Sabine Vogler, 2020. "The impact of managed entry agreements on pharmaceutical prices," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 47-62, October.
   7. Sebastian Jobjornsson & Martin Forster & Paolo Pertile & Carl-Fredrik Burman, 2015. "Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation," Discussion Papers 15/16, Department of Economics, University of York.
      • Jobjörnsson, Sebastian & Forster, Martin & Pertile, Paolo & Burman, Carl-Fredrik, 2016. "Late-stage pharmaceutical R&D and pricing policies under two-stage regulation," Journal of Health Economics, Elsevier, vol. 50(C), pages 298-311.
   8. Reyes Lorente & Fernando Antonanzas & Roberto Rodriguez-Ibeas, 2019. "Implementation of risk-sharing contracts as perceived by Spanish hospital pharmacists," Health Economics Review, Springer, vol. 9(1), pages 1-8, December.

10. Rosella Levaggi & Michele Moretto & Paolo Pertile, 2012. "DRGs: the link between investment in technologies and appropriateness," Working Papers 31/2012, University of Verona, Department of Economics.

    Cited by:

    1. Finocchiaro Castro, Massimo & Guccio, Calogero & Pignataro, Giacomo & Rizzo, Ilde, 2014. "The effects of reimbursement mechanisms on medical technology diffusion in the hospital sector in the Italian NHS," Health Policy, Elsevier, vol. 115(2), pages 215-229.

11. Rosella Levaggi & Michele Moretto & Paolo Pertile, 2010. "Static and Dynamic Efficiency of Irreversible Health Care Investments under Alternative Payment Rules," Working Papers 2010.130, Fondazione Eni Enrico Mattei.
    • Levaggi, R. & Moretto, M. & Pertile, P., 2012. "Static and dynamic efficiency of irreversible health care investments under alternative payment rules," Journal of Health Economics, Elsevier, vol. 31(1), pages 169-179.
    • Levaggi, Rosella & Moretto, Michele & Pertile, Paolo, 2010. "Static and Dynamic Efficiency of Irreversible Health Care Investments under Alternative Payment Rules," Institutions and Markets Papers 98047, Fondazione Eni Enrico Mattei (FEEM).

    Cited by:

    1. Ghandour, Ziad & Siciliani, Luigi & Straume, Odd Rune, 2022. "Investment and quality competition in healthcare markets," Journal of Health Economics, Elsevier, vol. 82(C).
       • Ziad Ghandour & Luigi Siciliani & Odd Rune Straume, 2021. "Investment and Quality Competition in Healthcare Markets," NIPE Working Papers 03/2021, NIPE - Universidade do Minho.
    2. Barros Pedro Pita & Martinez-Giralt Xavier, 2015. "Technological Adoption in Health Care – The Role of Payment Systems," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 15(2), pages 709-745, April.
    3. Kurt R. Brekke & Rosella Levaggi & Luigi Siciliani & Odd Rune Straume, 2015. "Patient mobility and health care quality when regions and patients differ in income," NIPE Working Papers 9/2015, NIPE - Universidade do Minho.
       • Brekke, Kurt R. & Levaggi, Rosella & Siciliani, Luigi & Straume, Odd Rune, 2016. "Patient mobility and health care quality when regions and patients differ in income," Journal of Health Economics, Elsevier, vol. 50(C), pages 372-387.
    4. Rosella Levaggi & Michele Moretto & Paolo Pertile, 2010. "Static and Dynamic Efficiency of Irreversible Health Care Investments under Alternative Payment Rules," Working Papers 2010.130, Fondazione Eni Enrico Mattei.
       • Levaggi, Rosella & Moretto, Michele & Pertile, Paolo, 2010. "Static and Dynamic Efficiency of Irreversible Health Care Investments under Alternative Payment Rules," Institutions and Markets Papers 98047, Fondazione Eni Enrico Mattei (FEEM).
       • Levaggi, R. & Moretto, M. & Pertile, P., 2012. "Static and dynamic efficiency of irreversible health care investments under alternative payment rules," Journal of Health Economics, Elsevier, vol. 31(1), pages 169-179.
    5. Levaggi, Rosella & Moretto, Michele & Pertile, Paolo, 2023. "Dynamic, incentive-compatible contracting for health services," FEEM Working Papers 338404, Fondazione Eni Enrico Mattei (FEEM).
       • Rosella Levaggi & Michele Moretto & Paolo Pertile, 2023. "Dynamic, incentive-compatible contracting for health services," Working Papers 2023.16, Fondazione Eni Enrico Mattei.
    6. Rosella Levaggi & Michele Moretto & Paolo Pertile, 2017. "The Dynamics of Pharmaceutical Regulation and R&D Investments," Journal of Public Economic Theory, Association for Public Economic Theory, vol. 19(1), pages 121-141, February.
       • Rosella Levaggi & Michele Moretto & Paolo Pertile, 2013. "The dynamics of pharmaceutical regulation and R&D investments," Working Papers 13/2013, University of Verona, Department of Economics.
    7. Levaggi, Rosella & Moretto, Michele & Pertile, Paolo, 2014. "Two-part payments for the reimbursement of investments in health technologies," Health Policy, Elsevier, vol. 115(2), pages 230-236.
    8. Michele Bisceglia & Roberto Cellini & Luca Grilli, 2019. "Quality Competition in Healthcare Services with Regional Regulators: A Differential Game Approach," Dynamic Games and Applications, Springer, vol. 9(1), pages 1-23, March.
       • Bisceglia, Michele & Cellini, Roberto & Grilli, Luca, 2017. "Quality competition in healthcare services with regional regulators: A differential game approach," MPRA Paper 81758, University Library of Munich, Germany.
    9. Michele Bisceglia & Roberto Cellini & Luca Grilli, 2018. "Regional regulators in health care service under quality competition: A game theoretical model," Health Economics, John Wiley & Sons, Ltd., vol. 27(11), pages 1821-1842, November.
       • Bisceglia, Michele & Cellini, Roberto & Grilli, Luca, 2017. "Regional regulators in healthcare service under quality competition: A game theoretical model," MPRA Paper 80507, University Library of Munich, Germany.
    10. Roberto Cellini & Domenico Lisi, 2020. "Readmission treatment price and product quality in the hospital sector," Health Economics, John Wiley & Sons, Ltd., vol. 29(1), pages 61-71, January.
    11. Annie Tubadji & Vassilis Angelis & Peter Nijkamp, 2016. "Endogenous intangible resources and their place in the institutional hierarchy," Review of Regional Research: Jahrbuch für Regionalwissenschaft, Springer;Gesellschaft für Regionalforschung (GfR), vol. 36(1), pages 1-28, February.
    12. Cellini, Roberto & Lisi, Domenico, 2019. "Readmission treatment price and product quality in the hospital sector: A note," MPRA Paper 92505, University Library of Munich, Germany.
    13. Rosella Levaggi & Michele Moretto & Paolo Pertile, 2012. "DRGs: the link between investment in technologies and appropriateness," Working Papers 31/2012, University of Verona, Department of Economics.
    14. Laurence C. Baker & Karine Lamiraud, 2022. "Adoption of hospital diagnosis‐related group financing in Switzerland and the availability of computed tomography scanners," Health Economics, John Wiley & Sons, Ltd., vol. 31(12), pages 2537-2557, December.

12. Paolo Pertile & Martin Forster & Davide La Torre, 2010. "Optimal sequential sampling rules for the economic evaluation of health technologies," Discussion Papers 10/24, Department of Economics, University of York.

    Cited by:

    1. Daniele Bregantini & Jacco J.J. Thijssen, 2014. "On a simple quickest detection rule for health-care technology assessment," Discussion Papers 14/01, Department of Economics, University of York.
    2. Stephen Chick & Martin Forster & Paolo Pertile, 2015. "A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response," Discussion Papers 15/09, Department of Economics, University of York.
       • Stephen Chick & Martin Forster & Paolo Pertile, 2017. "A Bayesian decision theoretic model of sequential experimentation with delayed response," Journal of the Royal Statistical Society Series B, Royal Statistical Society, vol. 79(5), pages 1439-1462, November.
    3. Martin Forster & Paolo Pertile, 2013. "Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective," Health Economics, John Wiley & Sons, Ltd., vol. 22(12), pages 1507-1514, December.
    4. Daniele Bregantini, 2014. "Don’t Stop ’Til You Get Enough: a quickest detection approach to HTA," Discussion Papers 14/04, Department of Economics, University of York.

Articles

1. Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).

   Cited by:

   1. Massimo FLORIO, 2020. "Biomed Europa: after the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly," CIRIEC Working Papers 2008, CIRIEC - Université de Liège.
      • Massimo Florio & Simona Gamba, 2021. "Biomed Europa: After the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly," Annals of Public and Cooperative Economics, Wiley Blackwell, vol. 92(3), pages 387-409, September.

2. Rosella Levaggi & Paolo Pertile, 2020. "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 357-362, June.

   Cited by:

   1. So-Young Ha & Dong-Won Kang & Hye-In Jung & Eui-Kyung Lee & Mi-Hai Park, 2022. "Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies," IJERPH, MDPI, vol. 19(7), pages 1-10, March.
   2. Rosella Levaggi & Paolo Pertile, 2021. "A reply to “Who would benefit from average value‐based pricing?”," Health Economics, John Wiley & Sons, Ltd., vol. 30(9), pages 2284-2286, September.
   3. Joan Costa‐Font & Rosella Levaggi, 2020. "Innovation, aging, and health care: Unraveling “silver” from “red” herrings?," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 3-7, October.

3. Rosella Levaggi & Paolo Pertile, 2020. "Which valued‐based price when patients are heterogeneous?," Health Economics, John Wiley & Sons, Ltd., vol. 29(8), pages 923-935, August.

   Cited by:

   1. Rosella Levaggi & Paolo Pertile, 2021. "A reply to “Who would benefit from average value‐based pricing?”," Health Economics, John Wiley & Sons, Ltd., vol. 30(9), pages 2284-2286, September.
   2. Joan Costa‐Font & Rosella Levaggi, 2020. "Innovation, aging, and health care: Unraveling “silver” from “red” herrings?," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 3-7, October.
   3. Doug Coyle, 2020. "Who would benefit from average value‐based pricing?," Health Economics, John Wiley & Sons, Ltd., vol. 29(8), pages 936-937, August.
   4. Simona Gamba & Paolo Pertile & Sabine Vogler, 2020. "The impact of managed entry agreements on pharmaceutical prices," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 47-62, October.

4. Simona Gamba & Paolo Pertile & Sabine Vogler, 2020. "The impact of managed entry agreements on pharmaceutical prices," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 47-62, October.

   Cited by:

   1. Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
   2. Joan Costa‐Font & Rosella Levaggi, 2020. "Innovation, aging, and health care: Unraveling “silver” from “red” herrings?," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 3-7, October.

5. Bucciol, Alessandro & Cavalli, Laura & Fedotenkov, Igor & Pertile, Paolo & Polin, Veronica & Sartor, Nicola & Sommacal, Alessandro, 2017. "A large scale OLG model for the analysis of the redistributive effects of policy reforms," European Journal of Political Economy, Elsevier, vol. 48(C), pages 104-127.

   Cited by:

   1. Boniface P Yemba & Inoussa Boubacar, 2018. "On the Merit of Debt Relief Programs in Heavily Indebted Poor Countries," Economics Bulletin, AccessEcon, vol. 38(2), pages 940-956.
   2. Benxi Lin & Zongjian Lin & Yu Yvette Zhang & Weiping Liu, 2018. "The Impact of the New Rural Pension Scheme on Retirement Sustainability in China: Evidence of Regional Differences in Formal and Informal Labor Supply," Sustainability, MDPI, vol. 10(12), pages 1-7, November.
   3. Michele Catalano & Emilia Pezzolla, 2022. "Global natural projections," Empirica, Springer;Austrian Institute for Economic Research;Austrian Economic Association, vol. 49(4), pages 949-990, November.
   4. Xiaohua Chen & Zaigui Yang, 2019. "Stochastically Assessing the Financial Sustainability of Individual Accounts in the Urban Enterprise Employees’ Pension Plan in China," Sustainability, MDPI, vol. 11(13), pages 1-20, June.
   5. Martino Tasso, 2020. "Do details matter? An analysis of Italian personal income tax," Temi di discussione (Economic working papers) 1301, Bank of Italy, Economic Research and International Relations Area.
   6. Lanying Sun & Changhao Su & Xinghui Xian, 2020. "Assessing the Sustainability of China’s Basic Pension Funding for Urban and Rural Residents," Sustainability, MDPI, vol. 12(7), pages 1-17, April.
   7. Alessandro Milazzo & Elena Vigna, 2018. "The Italian Pension Gap: A Stochastic Optimal Control Approach," Risks, MDPI, vol. 6(2), pages 1-20, April.
   8. Kichan Yoon & Gyubeom Park & Munjae Lee, 2020. "Priority Analysis of Right Remedies of Basic Living Recipients in Korea," Sustainability, MDPI, vol. 12(6), pages 1-9, March.
   9. Fedotenkov, Igor, 2018. "Corruption vs reforms: Why do voters prefer the former?," MPRA Paper 89581, University Library of Munich, Germany.
   10. Zhiping Song & Peishan Tong, 2022. "The Impact of Social Security Expenditure on Human Common Development: Evidence from China’s Provincial Panel Data," Sustainability, MDPI, vol. 14(17), pages 1-12, September.
   11. Oliwia Komada, 2023. "Raising America's future: search for optimal child-related transfers," GRAPE Working Papers 84, GRAPE Group for Research in Applied Economics.
   12. Damian Walczak & Jacek Wantoch-Rekowski & Robert Marczak, 2021. "Impact of Income on Life Expectancy: A Challenge for the Pension Policy," Risks, MDPI, vol. 9(4), pages 1-13, April.
   13. Julio López Laborda & Carmen Marín González & Jorge Onrubia, 2020. "Observatorio sobre el reparto de los impuestos y las prestaciones entre los hogares españoles. Quinto informe – Sanidad y educación, 2013 - 2017," Studies on the Spanish Economy eee2020-28, FEDEA.
   14. Ming Zhang & Xiaorong Zou & Long Sha, 2019. "Social Security and Sustainable Economic Growth: Based on the Perspective of Human Capital," Sustainability, MDPI, vol. 11(3), pages 1-14, January.
   15. Alessandro Milazzo & Elena Vigna, 2018. "“The Italian Pension Gap: a Stochastic Optimal Control Approach"," CeRP Working Papers 179, Center for Research on Pensions and Welfare Policies, Turin (Italy).
   16. Orlando Gomes, 2022. "Human capital and growth in an OLG-life cycle model," SN Business & Economics, Springer, vol. 2(1), pages 1-26, January.

6. Rosella Levaggi & Michele Moretto & Paolo Pertile, 2017. "The Dynamics of Pharmaceutical Regulation and R&D Investments," Journal of Public Economic Theory, Association for Public Economic Theory, vol. 19(1), pages 121-141, February.
   • Rosella Levaggi & Michele Moretto & Paolo Pertile, 2013. "The dynamics of pharmaceutical regulation and R&D investments," Working Papers 13/2013, University of Verona, Department of Economics.
   See citations under working paper version above.
7. Stephen Chick & Martin Forster & Paolo Pertile, 2017. "A Bayesian decision theoretic model of sequential experimentation with delayed response," Journal of the Royal Statistical Society Series B, Royal Statistical Society, vol. 79(5), pages 1439-1462, November.
   • Stephen Chick & Martin Forster & Paolo Pertile, 2015. "A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response," Discussion Papers 15/09, Department of Economics, University of York.
   See citations under working paper version above.
8. Jobjörnsson, Sebastian & Forster, Martin & Pertile, Paolo & Burman, Carl-Fredrik, 2016. "Late-stage pharmaceutical R&D and pricing policies under two-stage regulation," Journal of Health Economics, Elsevier, vol. 50(C), pages 298-311.
   • Sebastian Jobjornsson & Martin Forster & Paolo Pertile & Carl-Fredrik Burman, 2015. "Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation," Discussion Papers 15/16, Department of Economics, University of York.
   See citations under working paper version above.
9. Alessandro Bucciol & Laura Cavalli & Paolo Pertile & Veronica Polin & Alessandro Sommacal, 2016. "Redistribution at the local level: the case of public childcare in Italy," International Review of Economics, Springer;Happiness Economics and Interpersonal Relations (HEIRS), vol. 63(4), pages 359-378, December.
   • Alessandro Bucciol & Laura Cavalli & Paolo Pertile & Veronica Polin & Alessandro Sommacal, 2013. "Redistribution at the Local Level: The Case of Public Childcare in Italy," Working Papers 21/2013, University of Verona, Department of Economics.
   See citations under working paper version above.
10. Paolo Pertile & Veronica Polin & Pietro Rizza & Marzia Romanelli, 2015. "The fiscal disadvantage of young Italians: a new view on consolidation and fairness," The Journal of Economic Inequality, Springer;Society for the Study of Economic Inequality, vol. 13(1), pages 27-51, March.

    Cited by:

    1. Takeshi Miyazaki & Yukinobu Kitamura & Taro Ohno, 2019. "Income Tax Reforms and Redistribution by Age Group: Evidence from Japan," The Japanese Economic Review, Springer, vol. 70(1), pages 105-122, March.

11. Levaggi, Rosella & Moretto, Michele & Pertile, Paolo, 2014. "Two-part payments for the reimbursement of investments in health technologies," Health Policy, Elsevier, vol. 115(2), pages 230-236.

    Cited by:

    1. Ghandour, Ziad & Siciliani, Luigi & Straume, Odd Rune, 2022. "Investment and quality competition in healthcare markets," Journal of Health Economics, Elsevier, vol. 82(C).
       • Ziad Ghandour & Luigi Siciliani & Odd Rune Straume, 2021. "Investment and Quality Competition in Healthcare Markets," NIPE Working Papers 03/2021, NIPE - Universidade do Minho.
    2. Kurt R. Brekke & Rosella Levaggi & Luigi Siciliani & Odd Rune Straume, 2015. "Patient mobility and health care quality when regions and patients differ in income," NIPE Working Papers 9/2015, NIPE - Universidade do Minho.
       • Brekke, Kurt R. & Levaggi, Rosella & Siciliani, Luigi & Straume, Odd Rune, 2016. "Patient mobility and health care quality when regions and patients differ in income," Journal of Health Economics, Elsevier, vol. 50(C), pages 372-387.
    3. Levaggi, Rosella & Moretto, Michele & Pertile, Paolo, 2023. "Dynamic, incentive-compatible contracting for health services," FEEM Working Papers 338404, Fondazione Eni Enrico Mattei (FEEM).
       • Rosella Levaggi & Michele Moretto & Paolo Pertile, 2023. "Dynamic, incentive-compatible contracting for health services," Working Papers 2023.16, Fondazione Eni Enrico Mattei.
    4. Vogl, Matthias, 2014. "Hospital financing: Calculating inpatient capital costs in Germany with a comparative view on operating costs and the English costing scheme," Health Policy, Elsevier, vol. 115(2), pages 141-151.
    5. Michele Bisceglia & Roberto Cellini & Luca Grilli, 2019. "Quality Competition in Healthcare Services with Regional Regulators: A Differential Game Approach," Dynamic Games and Applications, Springer, vol. 9(1), pages 1-23, March.
       • Bisceglia, Michele & Cellini, Roberto & Grilli, Luca, 2017. "Quality competition in healthcare services with regional regulators: A differential game approach," MPRA Paper 81758, University Library of Munich, Germany.
    6. Michele Bisceglia & Roberto Cellini & Luca Grilli, 2018. "Regional regulators in health care service under quality competition: A game theoretical model," Health Economics, John Wiley & Sons, Ltd., vol. 27(11), pages 1821-1842, November.
       • Bisceglia, Michele & Cellini, Roberto & Grilli, Luca, 2017. "Regional regulators in healthcare service under quality competition: A game theoretical model," MPRA Paper 80507, University Library of Munich, Germany.

12. Paolo Pertile & Martin Forster & Davide La Torre, 2014. "Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 177(2), pages 419-438, February.

    Cited by:

    1. Stephen Chick & Martin Forster & Paolo Pertile, 2015. "A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response," Discussion Papers 15/09, Department of Economics, University of York.
       • Stephen Chick & Martin Forster & Paolo Pertile, 2017. "A Bayesian decision theoretic model of sequential experimentation with delayed response," Journal of the Royal Statistical Society Series B, Royal Statistical Society, vol. 79(5), pages 1439-1462, November.
    2. Oluwaseun Sharomi & Tufail Malik, 2017. "Optimal control in epidemiology," Annals of Operations Research, Springer, vol. 251(1), pages 55-71, April.
    3. Sebastian Sund & Lars H. Sendstad & Jacco J. J. Thijssen, 2022. "Kalman filter approach to real options with active learning," Computational Management Science, Springer, vol. 19(3), pages 457-490, July.
    4. Andres Alban & Stephen E. Chick & Martin Forster, 2023. "Value-Based Clinical Trials: Selecting Recruitment Rates and Trial Lengths in Different Regulatory Contexts," Management Science, INFORMS, vol. 69(6), pages 3516-3535, June.
    5. Thijssen, Jacco J.J. & Bregantini, Daniele, 2017. "Costly sequential experimentation and project valuation with an application to health technology assessment," Journal of Economic Dynamics and Control, Elsevier, vol. 77(C), pages 202-229.
    6. Williamson, S. Faye & Jacko, Peter & Jaki, Thomas, 2022. "Generalisations of a Bayesian decision-theoretic randomisation procedure and the impact of delayed responses," Computational Statistics & Data Analysis, Elsevier, vol. 174(C).
    7. Panos Kouvelis & Joseph Milner & Zhili Tian, 2017. "Clinical Trials for New Drug Development: Optimal Investment and Application," Manufacturing & Service Operations Management, INFORMS, vol. 19(3), pages 437-452, July.
    8. Stephen E. Chick & Noah Gans & Özge Yapar, 2022. "Bayesian Sequential Learning for Clinical Trials of Multiple Correlated Medical Interventions," Management Science, INFORMS, vol. 68(7), pages 4919-4938, July.

13. Martin Forster & Paolo Pertile, 2013. "Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective," Health Economics, John Wiley & Sons, Ltd., vol. 22(12), pages 1507-1514, December.

    Cited by:

    1. Daniele Bregantini & Jacco J.J. Thijssen, 2014. "On a simple quickest detection rule for health-care technology assessment," Discussion Papers 14/01, Department of Economics, University of York.
    2. Afschin Gandjour, 2015. "A model to optimize investments in health technologies, quality of care and research," Applied Economics, Taylor & Francis Journals, vol. 47(20), pages 2031-2039, April.
    3. Thijssen, Jacco J.J. & Bregantini, Daniele, 2017. "Costly sequential experimentation and project valuation with an application to health technology assessment," Journal of Economic Dynamics and Control, Elsevier, vol. 77(C), pages 202-229.
    4. Daniele Bregantini, 2014. "Don’t Stop ’Til You Get Enough: a quickest detection approach to HTA," Discussion Papers 14/04, Department of Economics, University of York.

14. Levaggi, R. & Moretto, M. & Pertile, P., 2012. "Static and dynamic efficiency of irreversible health care investments under alternative payment rules," Journal of Health Economics, Elsevier, vol. 31(1), pages 169-179.
    • Levaggi, Rosella & Moretto, Michele & Pertile, Paolo, 2010. "Static and Dynamic Efficiency of Irreversible Health Care Investments under Alternative Payment Rules," Institutions and Markets Papers 98047, Fondazione Eni Enrico Mattei (FEEM).
    • Rosella Levaggi & Michele Moretto & Paolo Pertile, 2010. "Static and Dynamic Efficiency of Irreversible Health Care Investments under Alternative Payment Rules," Working Papers 2010.130, Fondazione Eni Enrico Mattei.
    See citations under working paper version above.
15. Paolo Pertile & Emanuele Torri & Luciano Flor & Stefano Tardivo, 2009. "The timing of adoption of positron emission tomography: a real options approach," Health Care Management Science, Springer, vol. 12(3), pages 217-227, September.

    Cited by:

    1. Maarten Ijzerman & Lotte Steuten, 2011. "Early assessment of medical technologies to inform product development and market access," Applied Health Economics and Health Policy, Springer, vol. 9(5), pages 331-347, September.
    2. Rosella Levaggi & Michele Moretto & Paolo Pertile, 2010. "Static and Dynamic Efficiency of Irreversible Health Care Investments under Alternative Payment Rules," Working Papers 2010.130, Fondazione Eni Enrico Mattei.
       • Levaggi, Rosella & Moretto, Michele & Pertile, Paolo, 2010. "Static and Dynamic Efficiency of Irreversible Health Care Investments under Alternative Payment Rules," Institutions and Markets Papers 98047, Fondazione Eni Enrico Mattei (FEEM).
       • Levaggi, R. & Moretto, M. & Pertile, P., 2012. "Static and dynamic efficiency of irreversible health care investments under alternative payment rules," Journal of Health Economics, Elsevier, vol. 31(1), pages 169-179.

16. Paolo Pertile, 2009. "An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography," International Journal of Health Economics and Management, Springer, vol. 9(3), pages 317-332, September.

    Cited by:

    1. Fasterholdt, Iben & Krahn, Murray & Kidholm, Kristian & Yderstræde, Knud Bonnet & Pedersen, Kjeld Møller, 2017. "Review of early assessment models of innovative medical technologies," Health Policy, Elsevier, vol. 121(8), pages 870-879.
    2. Hui Zhang & Christian Wernz & Anthony D. Slonim, 2016. "Aligning incentives in health care: a multiscale decision theory approach," EURO Journal on Decision Processes, Springer;EURO - The Association of European Operational Research Societies, vol. 4(3), pages 219-244, November.
    3. Paolo Pertile, 2008. "Investment in Health Technologies in a Competitive Model with Real Options," Journal of Public Economic Theory, Association for Public Economic Theory, vol. 10(5), pages 923-952, October.

17. Paolo Pertile, 2008. "Investment in Health Technologies in a Competitive Model with Real Options," Journal of Public Economic Theory, Association for Public Economic Theory, vol. 10(5), pages 923-952, October.

    Cited by:

    1. Ghandour, Ziad & Siciliani, Luigi & Straume, Odd Rune, 2022. "Investment and quality competition in healthcare markets," Journal of Health Economics, Elsevier, vol. 82(C).
       • Ziad Ghandour & Luigi Siciliani & Odd Rune Straume, 2021. "Investment and Quality Competition in Healthcare Markets," NIPE Working Papers 03/2021, NIPE - Universidade do Minho.
    2. Meyer, Elisabeth & Rees, Ray, 2012. "Watchfully waiting: Medical intervention as an optimal investment decision," Journal of Health Economics, Elsevier, vol. 31(2), pages 349-358.
    3. Rosella Levaggi & Michele Moretto & Paolo Pertile, 2010. "Static and Dynamic Efficiency of Irreversible Health Care Investments under Alternative Payment Rules," Working Papers 2010.130, Fondazione Eni Enrico Mattei.
       • Levaggi, Rosella & Moretto, Michele & Pertile, Paolo, 2010. "Static and Dynamic Efficiency of Irreversible Health Care Investments under Alternative Payment Rules," Institutions and Markets Papers 98047, Fondazione Eni Enrico Mattei (FEEM).
       • Levaggi, R. & Moretto, M. & Pertile, P., 2012. "Static and dynamic efficiency of irreversible health care investments under alternative payment rules," Journal of Health Economics, Elsevier, vol. 31(1), pages 169-179.

18. Paolo Pertile, 2006. "Technology adoption, quality and health care costs: a review of the literature," STUDI ECONOMICI, FrancoAngeli Editore, vol. 2006(90), pages 81-107.

    Cited by:

    1. Michele Moretto & Rosella Levaggi, 2004. "Investment in Hospital Care Technology under Different Purchasing Rules: A Real Option Approach," Working Papers 2004.75, Fondazione Eni Enrico Mattei.
       • Rosella Levaggi & Moretto Michele, 2008. "Investment In Hospital Care Technology Under Different Purchasing Rules: A Real Option Approach," Bulletin of Economic Research, Wiley Blackwell, vol. 60(2), pages 159-181, April.
       • Rossella Levaggi & Michele Moretto, 2007. "Investment in hospital care technology under different purchasing rules: a real option approach," "Marco Fanno" Working Papers 0046, Dipartimento di Scienze Economiche "Marco Fanno".

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

Featured entries

This author is featured on the following reading lists, publication compilations, Wikipedia, or ReplicationWiki entries:

1. Associazione Italiana di Economia Sanitaria - AIES

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 14 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.

1. NEP-HEA: Health Economics (7) 2010-11-06 2010-12-11 2015-10-17 2018-06-18 2019-06-17 2023-09-25 2023-11-06. Author is listed
2. NEP-COM: Industrial Competition (4) 2013-08-05 2015-10-17 2018-06-18 2019-06-17
3. NEP-IND: Industrial Organization (3) 2013-08-05 2015-10-17 2016-10-30
4. NEP-INO: Innovation (3) 2013-08-05 2015-10-17 2019-06-17
5. NEP-REG: Regulation (3) 2013-08-05 2015-10-17 2018-06-18
6. NEP-CTA: Contract Theory and Applications (2) 2023-09-25 2023-11-06
7. NEP-DGE: Dynamic General Equilibrium (2) 2010-12-11 2015-12-20
8. NEP-EUR: Microeconomic European Issues (2) 2015-04-19 2022-09-12
9. NEP-CSE: Economics of Strategic Management (1) 2013-08-05
10. NEP-EEC: European Economics (1) 2015-12-20
11. NEP-HRM: Human Capital and Human Resource Management (1) 2015-04-19
12. NEP-IAS: Insurance Economics (1) 2015-04-19
13. NEP-NPS: Nonprofit and Public Sector (1) 2013-11-29
14. NEP-ORE: Operations Research (1) 2015-06-20
15. NEP-PBE: Public Economics (1) 2015-12-20
16. NEP-URE: Urban and Real Estate Economics (1) 2013-11-29

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Paolo Pertile should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.